Scientific Publications

Tumor microenvironment-derived S100A8/A9 is a novel prognostic biomarker for advanced melanoma patients and during immunotherapy with anti-PD-1 antibodies

Researchers investigated the efficacy of the tumor microenvironment-derived protein S100A8/A9 as a prognostic marker for melanoma patients, also in the setting of immunotherapy. Using a cDNA library and three independent tissue-microarrays (TMA), they analyzed S100A8/A9 gene and protein expression on melanocytic nevi, primary melanomas and metastases.

Read More
MRV News
Melanoma News
Archive
Menu